Physician profile
David W Starch
NPI 1184680209
$6,666.45
in general payments reported to CMS, 2019-2025
23 companies · $968 in 2025
The $968 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $1,236 · 2021: $334 · 2022: $1,986 · 2023: $824 · 2024: $389 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,181.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $3,176.40 | 2019-2022 | |
| Amgen INC. | $469.92 | 2023-2025 | Tavneos, Otezla, Repatha |
| Abbott Laboratories | $444.99 | 2019-2023 | Octrode |
| Pacira Pharmaceuticals Incorporated | $384.80 | 2019-2025 | Exparel, Iovera, Zilretta |
| Medtronic, INC. | $259.59 | 2023-2025 | Venaseal, Inceptiv |
| Pacira Therapeutics, INC. | $245.72 | 2019-2021 | |
| Smith+Nephew, INC. | $197.38 | 2019-2025 | Journey II, K-15 Pork, Real Intelligence |
| Davol INC. | $197.38 | 2022-2023 | |
| Si-Bone, INC. | $161.32 | 2025 | |
| Anika Therapeutics, INC. | $147.78 | 2021-2024 | Revomotion |
| Medinc of Texas | $140.52 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $131.40 | 2023 | |
| Abbvie INC. | $121.71 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.42 | 2024 | |
| Cardiovascular Systems INC. | $103.62 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $80.57 | 2025 | Pangea |
| Mission Medical Distribution, LLC | $72.12 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $54.27 | 2024-2025 | |
| Breg, INC | $53.04 | 2020-2022 | |
| Fidia Pharma USA INC. | $48.81 | 2024-2025 | Hymovis, Triluron |
| Endo Pharmaceuticals INC. | $25.19 | 2019 | |
| Arthrosurface Incorporated | $19.91 | 2025 | Ovomotion |
| Bioventus LLC | $18.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Starch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.